➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Dow
Moodys
McKesson
Colorcon

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,937,181

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,937,181
Title:Tofacitinib oral sustained release dosage forms
Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Inventor(s): Herbig; Scott Max (East Lyme, CT), Krishnaswami; Sriram (East Lyme, CT), Kushner, IV; Joseph (Bradford, RI), Lamba; Manisha (Waterford, CT), Stock; Thomas C (Chester Springs, PA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:14/211,659
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,937,181
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Device; Dosage form;

Drugs Protected by US Patent 9,937,181

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer XELJANZ XR tofacitinib citrate TABLET, EXTENDED RELEASE;ORAL 208246-001 Feb 23, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,937,181

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 095487   Start Trial
Australia 2014233850   Start Trial
Australia 2017203334   Start Trial
Brazil 112015020453   Start Trial
Canada 2905604   Start Trial
Canada 3037328   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKesson
AstraZeneca
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.